Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study validated a protocol for inducing surface ectoderm differentiation from human induced pluripotent stem cells and highlighted the role of TGFβ signaling pathways in this process.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This review discusses the uncertain role of immune factors, particularly autoantibodies, in the development of alopecia areata and emphasizes that identifying key autoantigens could lead to targeted immunotherapies.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This study found that NK and CD8+ T cell infiltration may drive inflammation in androgenetic alopecia, suggesting that targeting IL-15 signaling could offer a new therapeutic approach for hair regeneration.

This review highlights that a comprehensive approach combining pharmacological, immunomodulatory, and regenerative interventions, including phototherapy enhanced with topical treatments and JAK inhibitors, appears effective and promising in the management of vitiligo by addressing its autoimmune and melanocyte-loss aspects.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

This study found that COL17 deficiency in neonatal mice causes abnormal skin cell proliferation due to disrupted Wnt signaling, while replenishing or overexpressing COL17 can reverse this effect in both neonatal and aged skin.

This study examined the current clinical practices for diagnosing and managing alopecia areata in Poland, finding that patient care is inadequate and falls short in using validated severity tools and providing access to advanced therapies despite the availability of new medications like Janus kinase inhibitors.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This review synthesizes recent molecular and preclinical advances in alopecia areata and androgenetic alopecia, highlighting how interventions targeting specific intracellular signaling pathways and utilizing stem cell technologies can support precision regrowth and structural follicle reconstruction.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This review discusses the role of exosomes in medical aesthetics, focusing on their mechanisms, production, and preservation, but reports no new clinical results and highlights barriers to their widespread application.

This review discusses recent advancements in the study and application of epidermal stem cells for wound healing and tissue engineering, without presenting new experimental findings.

This review provides an analysis of topical treatments with clinically proven efficacy for managing hyperpigmentation and concludes that the most effective approach is using combined therapies that target multiple aspects of skin pigmentation physiology.

Stretching skin increases a certain protein that attracts stem cells, helping skin regeneration.

In this study, researchers identified specific long non-coding RNAs involved in feather development that do not follow traditional genetic inheritance patterns in chickens.

This review explores the shared pathogenesis of alopecia areata and vitiligo and compares treatment responses, noting that hair regrowth in alopecia areata occurs more rapidly than skin re-pigmentation in vitiligo, possibly due to differences in stem cell biology and treatment effects on melanocytes.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.